KNApSAcK Metabolite C00001244
Metabolite
KNApSAcK Entry
| id | C00001244 |
|---|---|
| Name | Diallyl sulfide |
| CAS RN | 592-88-1 |
| Standard InChI | InChI=1S/C6H10S/c1-3-5-7-6-4-2/h3-4H,1-2,5-6H2 |
| Standard InChI (Main Layer) | InChI=1S/C6H10S/c1-3-5-7-6-4-2/h3-4H,1-2,5-6H2 |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 7212 |
Link
ChEMBL
| By standard InChI | CHEMBL170458 |
|---|---|
| By standard InChI Main Layer | CHEMBL170458 |
KEGG
| By LinkDB | C08370 |
|---|
CTD
| By CAS RN | C038491 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| Liliopsida | 1 |
Family
| family name | count |
|---|---|
| Amaryllidaceae | 1 |
List (1)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Allium sativum | 4682 | Amaryllidaceae | Liliopsida | Viridiplantae |
Human Protein / Gene in interaction
6 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| Q16637 | Survival motor neuron protein | Unclassified protein | CHEMBL170458 |
CHEMBL1613842
(1)
|
4 / 2 |
| P08183 | Multidrug resistance protein 1 | drug | CHEMBL170458 |
CHEMBL2075504
(1)
CHEMBL2075295
(1)
|
1 / 0 |
| O75762 | Transient receptor potential cation channel subfamily A member 1 | Unclassified protein | CHEMBL170458 |
CHEMBL1118238
(1)
|
1 / 0 |
| P37088 | Amiloride-sensitive sodium channel subunit alpha | NA | CHEMBL170458 |
CHEMBL2051232
(1)
|
2 / 2 |
| P51168 | Amiloride-sensitive sodium channel subunit beta | Unclassified protein | CHEMBL170458 |
CHEMBL2051232
(1)
|
3 / 3 |
| P51170 | Amiloride-sensitive sodium channel subunit gamma | Unclassified protein | CHEMBL170458 |
CHEMBL2051232
(1)
|
2 / 3 |
CTD interaction (37)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C038491 | 5243 |
ABCB1
ABC20 CD243 CLCS GP170 MDR1 P-GP PGY1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) | allyl sulfide results in increased expression of ABCB1 mRNA |
increases expression
|
mRNA |
22397993
|
| C038491 | 4363 |
ABCC1
ABC29 ABCC GS-X MRP MRP1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | allyl sulfide results in decreased expression of ABCC1 mRNA |
decreases expression
|
mRNA |
22397993
|
| C038491 | 8714 |
ABCC3
ABC31 EST90757 MLP2 MOAT-D MRP3 cMOAT2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | allyl sulfide affects the expression of ABCC3 mRNA |
affects expression
|
mRNA |
22397993
|
| C038491 | 10257 |
ABCC4
EST170205 MOAT-B MOATB MRP4 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | allyl sulfide results in decreased expression of ABCC4 mRNA |
decreases expression
|
mRNA |
22397993
|
| C038491 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | [allyl sulfide co-treated with resveratrol] results in increased expression of BAX mRNA |
affects cotreatment
/ increases expression |
mRNA |
18512326
|
| C038491 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | allyl sulfide results in increased expression of BAX mRNA |
increases expression
|
mRNA |
17647244
|
| C038491 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | allyl sulfide results in increased expression of BAX protein |
increases expression
|
protein |
17647244
|
| C038491 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | [allyl sulfide co-treated with resveratrol] results in decreased expression of BCL2 mRNA |
affects cotreatment
/ decreases expression |
mRNA |
18512326
|
| C038491 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | allyl sulfide results in decreased expression of BCL2 mRNA |
decreases expression
|
mRNA |
17647244
|
| C038491 | 330 |
BIRC3
AIP1 API2 CIAP2 HAIP1 HIAP1 MALT2 MIHC RNF49 c-IAP2 |
baculoviral IAP repeat containing 3 | allyl sulfide results in decreased expression of BIRC3 protein |
decreases expression
|
protein |
17647244
|
| C038491 | 332 |
BIRC5
API4 EPR-1 |
baculoviral IAP repeat containing 5 | allyl sulfide results in decreased expression of BIRC5 protein |
decreases expression
|
protein |
17647244
|
| C038491 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | allyl sulfide results in increased activity of CASP3 protein |
increases activity
|
protein |
17647244
|
| C038491 | 837 |
CASP4
ICE(rel)II ICEREL-II ICH-2 Mih1/TX TX |
caspase 4, apoptosis-related cysteine peptidase (EC:3.4.22.57) | allyl sulfide results in increased activity of CASP4 protein |
increases activity
|
protein |
17647244
|
| C038491 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | allyl sulfide results in increased activity of CASP9 protein |
increases activity
|
protein |
17647244
|
| C038491 | 831 |
CAST
BS-17 |
calpastatin | allyl sulfide results in decreased expression of CAST mRNA |
decreases expression
|
mRNA |
17647244
|
| C038491 | 831 |
CAST
BS-17 |
calpastatin | allyl sulfide results in decreased expression of CAST protein |
decreases expression
|
protein |
17647244
|
| C038491 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | allyl sulfide results in increased expression of CDKN1A mRNA |
increases expression
|
mRNA |
17937621
|
| C038491 | 1543 |
CYP1A1
AHH AHRR CP11 CYP1 P1-450 P450-C P450DX |
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | allyl sulfide results in decreased activity of CYP1A1 protein |
decreases activity
|
protein |
18339364
|
| C038491 | 1548 |
CYP2A6
CPA6 CYP2A CYP2A3 CYPIIA6 P450C2A P450PB |
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) | allyl sulfide results in decreased activity of CYP2A6 protein |
decreases activity
|
protein |
18339364
|
| C038491 | 24300 | allyl sulfide results in increased expression of CYP2B1 mRNA |
increases expression
|
mRNA |
17353348
|
||
| C038491 | 361523 | allyl sulfide results in increased expression of CYP2B2 mRNA |
increases expression
|
mRNA |
17353348
|
||
| C038491 | 1555 |
CYP2B6
CPB6 CYP2B CYP2B7 CYP2B7P CYPIIB6 EFVM IIB1 P450 |
cytochrome P450, family 2, subfamily B, polypeptide 6 (EC:1.14.14.1) | allyl sulfide results in increased expression of CYP2B6 mRNA |
increases expression
|
mRNA |
17353348
|
| C038491 | 1571 |
CYP2E1
CPE1 CYP2E P450-J P450C2E |
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]] |
affects cotreatment
/ decreases reaction / increases response to substance |
protein |
12086689
|
| C038491 | 1571 |
CYP2E1
CPE1 CYP2E P450-J P450C2E |
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | allyl sulfide inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] |
decreases reaction
/ increases expression |
protein |
22138249
|
| C038491 | 1571 |
CYP2E1
CPE1 CYP2E P450-J P450C2E |
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | allyl sulfide results in decreased activity of CYP2E1 protein |
decreases activity
|
protein |
15974642
17034788 18339364 |
| C038491 | 56616 |
DIABLO
DFNA64 SMAC |
diablo, IAP-binding mitochondrial protein | allyl sulfide results in decreased localization of DIABLO protein |
decreases localization
|
protein |
17647244
|
| C038491 | 355 |
FAS
ALPS1A APO-1 APT1 CD95 FAS1 FASTM TNFRSF6 |
Fas cell surface death receptor | [allyl sulfide co-treated with resveratrol] results in increased expression of FAS protein |
affects cotreatment
/ increases expression |
protein |
18512326
|
| C038491 | 1647 |
GADD45A
DDIT1 GADD45 |
growth arrest and DNA-damage-inducible, alpha | allyl sulfide results in increased expression of GADD45A mRNA |
increases expression
|
mRNA |
17937621
|
| C038491 | 2950 |
GSTP1
DFN7 FAEES3 GST3 GSTP PI |
glutathione S-transferase pi 1 (EC:2.5.1.18) | allyl sulfide results in increased expression of GSTP1 mRNA |
increases expression
|
mRNA |
17937621
|
| C038491 | 5599 |
MAPK8
JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8 SAPK1 SAPK1c |
mitogen-activated protein kinase 8 (EC:2.7.11.24) | allyl sulfide results in increased phosphorylation of and results in increased activity of MAPK8 protein |
increases activity
/ increases phosphorylation |
protein |
17647244
|
| C038491 | 10397 |
NDRG1
CAP43 CMT4D DRG-1 DRG1 GC4 HMSNL NDR1 NMSL PROXY1 RIT42 RTP TARG1 TDD5 |
N-myc downstream regulated 1 | allyl sulfide results in increased expression of NDRG1 mRNA |
increases expression
|
mRNA |
17937621
|
| C038491 | 1728 |
NQO1
DHQU DIA4 DTD NMOR1 NMORI QR1 |
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) | allyl sulfide results in increased expression of NQO1 mRNA |
increases expression
|
mRNA |
17353348
|
| C038491 | 5465 |
PPARA
NR1C1 PPAR PPARalpha hPPAR |
peroxisome proliferator-activated receptor alpha | allyl sulfide inhibits the reaction [Ethanol results in decreased expression of PPARA protein] |
decreases expression
/ decreases reaction |
protein |
22138249
|
| C038491 | 5743 |
PTGS2
COX-2 COX2 GRIPGHS PGG/HS PGHS-2 PHS-2 hCox-2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | allyl sulfide results in decreased activity of PTGS2 protein |
decreases activity
|
protein |
15523159
|
| C038491 | 6720 |
SREBF1
SREBP-1c SREBP1 bHLHd1 |
sterol regulatory element binding transcription factor 1 | allyl sulfide inhibits the reaction [Ethanol results in increased expression of SREBF1 protein] |
decreases reaction
/ increases expression |
protein |
22138249
|
| C038491 | 7296 |
TXNRD1
GRIM-12 TR TR1 TRXR1 TXNR |
thioredoxin reductase 1 (EC:1.8.1.9) | allyl sulfide results in increased activity of TXNRD1 protein |
increases activity
|
protein |
17937621
|
| C038491 | 331 |
XIAP
API3 BIRC4 IAP-3 ILP1 MIHA XLP2 hIAP-3 hIAP3 |
X-linked inhibitor of apoptosis | allyl sulfide results in decreased expression of XIAP protein |
decreases expression
|
protein |
17647244
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (11)
| OMIM | preferred title | UniProt |
|---|---|---|
| #211400 | Bronchiectasis with or without elevated sweat chloride 1; besc1 |
P51168
|
| #613021 | Bronchiectasis with or without elevated sweat chloride 2; besc2 |
P37088
|
| #613071 | Bronchiectasis with or without elevated sweat chloride 3; besc3 |
P51170
|
| #615040 | Episodic pain syndrome, familial, 1; feps1 |
O75762
|
| #612244 | Inflammatory bowel disease 13; ibd13 |
P08183
|
| #177200 | Liddle syndrome |
P51168
P51170 |
| #264350 | Pseudohypoaldosteronism, type i, autosomal recessive; pha1b |
P37088
P51168 |
| #253300 | Spinal muscular atrophy, type i; sma1 |
Q16637
|
| #253550 | Spinal muscular atrophy, type ii; sma2 |
Q16637
|
| #253400 | Spinal muscular atrophy, type iii; sma3 |
Q16637
|
| #271150 | Spinal muscular atrophy, type iv; sma4 |
Q16637
|
KEGG DISEASE (4)
| KEGG | disease name | UniProt |
|---|---|---|
| H00243 | Hyperkalemic distal renal tubular acidosis (RTA type 4) |
P37088
(related)
P51168 (related) P51170 (related) |
| H00892 | Bronchiectasis with or without elevated sweat chloride |
P37088
(related)
P51168 (related) P51170 (related) |
| H00242 | Liddle syndrome |
P51168
(related)
P51170 (related) |
| H00455 | Spinal muscular atrophy (SMA) |
Q16637
(related)
Q16637 (related) |
Diseases related to CTD interactions
8 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D001943 | C038491 | Breast Neoplasms |
therapeutic
|
17125941
|
|
| D056486 | C038491 | Drug-Induced Liver Injury |
therapeutic
|
12060674
15950962 20116195 |
|
| D005235 | C038491 | Fatty Liver, Alcoholic |
therapeutic
|
22138249
|
|
| D006525 | C038491 | Hepatitis, Viral, Human |
therapeutic
|
15950962
|
|
| D006965 | C038491 | Hyperplasia |
marker/mechanism
|
20116195
|
|
| D008113 | C038491 | Liver Neoplasms |
therapeutic
|
7852184
|
|
| D009404 | C038491 | Nephrotic Syndrome |
therapeutic
|
11055549
|
|
| D012878 | C038491 | Skin Neoplasms |
therapeutic
|
2105358
|